Shares of Zoetis Inc (NYSE:ZTS) have been given an average rating of “Buy” by the nineteen research firms that are currently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and eleven have given a buy rating to the company. The average 12-month price target among analysts that have covered the stock in the last year is $84.73.
Several equities research analysts have commented on the stock. Cantor Fitzgerald set a $98.00 target price on shares of Zoetis and gave the stock a “buy” rating in a research report on Wednesday, June 6th. BMO Capital Markets restated a “hold” rating and set a $80.00 target price on shares of Zoetis in a research report on Wednesday, May 16th. Craig Hallum restated a “buy” rating and set a $94.00 target price (up from $87.00) on shares of Zoetis in a research report on Wednesday, April 25th. Hilliard Lyons lowered shares of Zoetis to a “neutral” rating in a research report on Thursday, April 19th. They noted that the move was a valuation call. Finally, Citigroup restated a “buy” rating and set a $98.00 target price (up from $85.00) on shares of Zoetis in a research report on Thursday, April 19th.
Shares of Zoetis traded down $0.69, hitting $84.01, during trading on Tuesday, according to MarketBeat. 3,137,841 shares of the company were exchanged, compared to its average volume of 2,703,711. The firm has a market capitalization of $41.53 billion, a P/E ratio of 35.00, a PEG ratio of 1.90 and a beta of 0.98. Zoetis has a 1 year low of $59.50 and a 1 year high of $89.25. The company has a debt-to-equity ratio of 2.51, a quick ratio of 2.83 and a current ratio of 4.27.
Zoetis (NYSE:ZTS) last issued its earnings results on Wednesday, May 2nd. The company reported $0.75 EPS for the quarter, topping the consensus estimate of $0.69 by $0.06. The company had revenue of $1.37 billion for the quarter, compared to analyst estimates of $1.35 billion. Zoetis had a net margin of 17.97% and a return on equity of 68.51%. The business’s revenue was up 11.0% on a year-over-year basis. During the same period in the previous year, the firm earned $0.53 EPS. sell-side analysts forecast that Zoetis will post 3.06 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 4th. Investors of record on Friday, July 20th will be paid a $0.126 dividend. This represents a $0.50 annualized dividend and a yield of 0.60%. The ex-dividend date of this dividend is Thursday, July 19th. Zoetis’s payout ratio is 20.83%.
In related news, insider Kristin C. Peck sold 4,877 shares of the business’s stock in a transaction dated Tuesday, May 1st. The shares were sold at an average price of $83.46, for a total value of $407,034.42. Following the completion of the transaction, the insider now owns 42,652 shares of the company’s stock, valued at approximately $3,559,735.92. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 0.35% of the company’s stock.
Hedge funds have recently made changes to their positions in the stock. BlackRock Inc. grew its holdings in Zoetis by 6.7% in the 1st quarter. BlackRock Inc. now owns 41,069,741 shares of the company’s stock valued at $3,429,736,000 after buying an additional 2,584,199 shares during the period. Clearbridge Investments LLC grew its holdings in Zoetis by 3.9% in the 4th quarter. Clearbridge Investments LLC now owns 9,512,060 shares of the company’s stock valued at $685,249,000 after buying an additional 353,622 shares during the period. Polen Capital Management LLC grew its holdings in Zoetis by 125.3% in the 1st quarter. Polen Capital Management LLC now owns 8,943,633 shares of the company’s stock valued at $746,883,000 after buying an additional 4,974,081 shares during the period. Brown Advisory Inc. grew its holdings in Zoetis by 2.1% in the 4th quarter. Brown Advisory Inc. now owns 7,207,114 shares of the company’s stock valued at $519,200,000 after buying an additional 149,095 shares during the period. Finally, Northern Trust Corp grew its holdings in Zoetis by 1.4% in the 1st quarter. Northern Trust Corp now owns 5,948,527 shares of the company’s stock valued at $496,762,000 after buying an additional 82,183 shares during the period. 90.10% of the stock is owned by hedge funds and other institutional investors.
Zoetis Company Profile
Zoetis Inc discovers, develops, manufactures, and markets veterinary vaccines and medicines in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.